Highlights

• Imricor Medical Systems shares rose 11.91% to AUD 2.02 during the afternoon session on 2 July 2026.

• The company received FDA 510(k) clearance for pediatric label expansion of its NorthStar system.

• Imricor also received FDA 510(k) clearance for pediatric use of its Vision-MR Diagnostic Catheter.

• The clearances allow both products to be marketed for patients of any age, including children and young adults.

• The update supports Imricor’s U.S. commercialisation strategy and opens pediatric iMR-guided applications.

• More than 250,000 diagnostic right and left heart catheterisations are performed annually in the U.S. across adult and children’s hospitals.

Imricor Medical Systems, Inc. (ASX:IMR) shares moved sharply higher during the afternoon session on 2 July 2026 after the company announced two U.S. Food and Drug Administration 510(k) clearances linked to pediatric use. The stock rose 11.91% to AUD 2.02, adding AUD 0.22 during the session. Over the past year, Imricor shares remain up 28.66%, reflecting a gain of AUD 0.45.

The latest update is clearly favourable for Imricor, as it expands the approved labelling of both NorthStar® and the Vision-MR® Diagnostic Catheter to include pediatric use. The clearances enable the company to market these products for patients of any age, including children and young adults, and support its broader U.S. commercialisation strategy in interventional magnetic resonance procedures.

Imricor Medical Systems is a medical technology company focused on enabling interventional procedures to be performed under real-time magnetic resonance guidance rather than traditional X-ray fluoroscopy. The company’s technology is designed to use the imaging capabilities of magnetic resonance while reducing or eliminating procedure-related radiation exposure. Its product portfolio includes capital equipment such as the NorthStar Mapping System and the Advantage-MR EP Recorder/Stimulator, alongside single-use devices including diagnostic catheters, ablation catheters, steerable sheaths and related tools used in cardiac procedures.

FDA Clears NorthStar for Pediatric Use

The central development in the announcement is Imricor’s receipt of FDA 510(k) clearance for pediatric label expansion of its NorthStar system.

NorthStar is described by Imricor as the world’s first and only MR-native 3D interventional magnetic resonance mapping and guidance system. The system is designed to support procedures performed under real-time magnetic resonance imaging guidance.

The latest clearance follows the company’s January 2026 announcement that NorthStar had received FDA clearance for use in adult patients. Imricor later submitted NorthStar for pediatric labelling expansion in April 2026.

With the latest FDA clearance, NorthStar can now be marketed for use across all age groups, including children and young adults. This is important because pediatric patients with cardiac conditions may undergo multiple procedures at a young age, making radiation reduction a central clinical consideration.

Vision-MR Diagnostic Catheter Also Receives Pediatric Clearance

Alongside NorthStar, Imricor also received FDA 510(k) clearance for pediatric label expansion of its Vision-MR Diagnostic Catheter.

The company said this concurrent clearance creates a more complete set of pediatric interventional magnetic resonance devices. During discussions with the FDA in the review process, Imricor decided to submit the Vision-MR Diagnostic Catheter for pediatric label expansion as well.

The catheter provides an actively tracked tool for use in the iMR lab for diagnostic electrophysiological applications. Imricor noted that this application is linked to future use once the Advantage-MR EP Recorder/Stimulator is cleared by the FDA.

By securing pediatric label expansion for both NorthStar and the Vision-MR Diagnostic Catheter, Imricor is strengthening the product set available for pediatric interventional magnetic resonance procedures in the U.S.

Clearances Open Door to Pediatric iMR Applications

The FDA clearances allow Imricor to market NorthStar and the Vision-MR Diagnostic Catheter for use in patients of any age.

This includes children and young adults treated across more than 250 children’s hospitals in the United States.

Pediatric patients who may benefit from interventional magnetic resonance procedures include children born with congenital heart defects who require multiple cardiac catheterisations early in life.

Imricor highlighted that younger patients are more sensitive to ionising X-ray radiation exposure. Because iMR procedures eliminate procedure-related X-rays, the company sees pediatric applications as a meaningful opportunity for its technology.

The clearances also open the door for iMR-guided pediatric applications such as cardiac catheterisations, where procedures that may previously have involved an MRI scan followed by an X-ray lab intervention could potentially be completed in the iMR environment.

Diagnostic Interventions Represent New Market Opportunity

Imricor said diagnostic interventions represent a new market for the company, built from the NorthStar platform.

More than 250,000 diagnostic right and left heart catheterisations are performed annually in the United States across adult and children’s hospitals.

The company believes NorthStar and the Vision-MR Diagnostic Catheter can support diagnostic procedures by allowing them to be performed under magnetic resonance guidance rather than relying on traditional X-ray fluoroscopy workflows.

According to Imricor, what has typically required an MRI scan followed by an X-ray lab intervention can now be performed in the iMR setting. The company said this may deliver time and cost savings for hospitals.

The announcement positions pediatric applications as an early commercial channel ahead of broader U.S. adoption of the company’s full electrophysiology platform in adult hospitals.

Pediatric Hospitals Seen as Early Commercial Channel

Imricor said the pediatric market represents an attractive early commercial channel for NorthStar and the Vision-MR Diagnostic Catheter.

Children’s hospitals often have a high level of interest in reducing radiation exposure and limiting the use of contrast dyes for patients. These priorities align with Imricor’s focus on interventional procedures performed under magnetic resonance guidance.

The company also noted that NorthStar may help improve iMR procedure workflows that are currently performed using standard magnetic resonance imaging system interfaces.

By providing a navigation system designed for use in iMR procedures, NorthStar could support more efficient procedure guidance in pediatric settings.

This is relevant to Imricor’s U.S. commercialisation pathway because pediatric hospitals may adopt iMR-guided diagnostic and interventional workflows before broader adult hospital deployment of the company’s full platform.

Clearances Support U.S. Commercialisation Strategy

The latest FDA clearances are another step in Imricor’s U.S. commercialisation strategy.

NorthStar had already received FDA clearance for adult use earlier in 2026. The pediatric expansion now broadens the addressable use cases for the system and allows the company to market it across all age groups.

The Vision-MR Diagnostic Catheter clearance adds another piece to the product offering for iMR-guided procedures.

Imricor’s products are already approved in the European Union, the Kingdom of Saudi Arabia and New Zealand. NorthStar is also approved in the United States.

The company’s broader product suite includes MR-compatible tools designed for cardiac catheter ablation procedures, including capital equipment and single-use devices. The pediatric clearances add a new near-term pathway within the U.S. market while the company continues developing its broader platform.

Management Highlights Pediatric Patient Benefit

Imricor Chair and CEO Steve Wedan said the company does not intend to limit its products only to certain patient groups where radiation-free iMR procedures may be useful.

He highlighted the importance of delivering technology to infants and young children, noting that changing interventional medicine for doctors and patients means changing it for all doctors and all patients.

Management commentary focused on the clinical relevance of radiation-free procedures for pediatric patients rather than only the commercial impact. This is consistent with the company’s emphasis on magnetic resonance guidance as a way to improve safety and procedure quality.

Why the Update Matters for Hospitals

The announcement also has relevance for hospital workflows.

According to Imricor, a procedure pathway that has often required a diagnostic MRI scan followed by an X-ray-guided intervention may now be able to take place within the iMR environment.

For hospitals, this could reduce workflow duplication by combining imaging and intervention within a magnetic resonance setting. The company said this can support time and cost savings.

For pediatric centres, the ability to reduce radiation exposure while using real-time magnetic resonance guidance may be particularly relevant because children with congenital heart conditions may require repeated procedures over time.

The use of NorthStar as a navigation system and Vision-MR Diagnostic Catheter as an actively tracked device provides a product foundation for these procedures.

What This Means for Investors?

Imricor’s latest FDA clearances appear to have supported the share price jump because they expand the company’s U.S. product opportunity into pediatric applications. The clearances allow NorthStar and the Vision-MR Diagnostic Catheter to be marketed for patients of any age, including children and young adults. This opens a potential early commercial channel across more than 250 U.S. children’s hospitals and supports iMR-guided cardiac catheterisation applications. For investors, the key focus is now on how Imricor converts these clearances into commercial adoption, particularly as diagnostic interventions become a new market for the company ahead of broader adult hospital uptake of its full platform.

FAQs